Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide aqueous solution in acute arterial ischaemic stroke
2021-006126-52Phase 2Active
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Oct 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Afamelanotide in acute ischemic stroke (AIS) and ischemic stroke, sponsored by Clinuvel Pharmaceuticals. Primary endpoint: Safety of afamelanotide. Started Oct 2022; status: active.
02
Drugs
Afamelanotide
03
Conditions
acute ischemic stroke (AIS)ischemic stroke
Beyond the preview
Go deeper on 2021-006126-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006126-52.